Parent and group
- BIORED65.57%
PROTEA BIOPHARMA NV
ActiveSummary
The computed 12-month bankruptcy probability of PROTEA BIOPHARMA NV is 7.4% (elevated). For PROTEA BIOPHARMA NV, at least two annual filings are missing. The 2023 annual accounts show negative equity (-€999,054) and a net result of -€44,940. Equity has been shrinking by about 23% per year since 2018. Its solvency ranks better than 6% of 591 sector peers (NACE 72, financial year 2023). The company has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 10-11-2009 Normal situation
- Activity
- Research and development on biotechnology NACE 72101and 1 other
- Establishment unit
- 2.183.352.808 1120 Brussel, since 10-11-2009
- Financial year end
- 31 December
- Peppol
- Reachable since 30-12-2025
Board and ownership
Board
- DECONINCK FrankDirector
- Deslypere Jean-PaulDirector · since 22-02-2022
- ANNA CLOOFDirector
Shareholders
- NV R.E.D. LABORATORIES99.99%· score 842025 annual accounts of NV R.E.D. LABORATORIES
- Holdings
- Shares in 1 company KALIDA BV
Financial position
- Bankruptcy probabilitywithin 12 months
- 7.4%
2023 figures too old to score
Annual accounts 2023
- Gross margin
- -€41,839
- ▲ 75.8%
- Loss
- €44,940
- ▼ 81.6%
- Equity
- -€999,054
- ▼ 4.7%
- Total assets
- €1.3m
- ▲ 1.3%
- Negative equity on 31-12-2023
- 2024 accounts not filed, 459 days past the deadline
Turnover not published (abbreviated or micro format)Net result +82%: other schema
Signalsraises riskFigures for financial year 2023 (filed on 06-09-2024)2 financial years not filed after the legal deadline; last filed accounts filed 29 days late; 1 of the last 3 accounts lateLiquidity: current ratio 1.23, cash €3,072Two or more financial years not filed2023 accounts filed 29 days latelowers riskSector: Scientific research and development (NACE 72)Show the evidence
Bankruptcy probability
No current score
Figures too old
The latest figures are for FY 2023. They are too old for a current score.
Bankruptcy probability: Elevated
Filing: At least two annual filings are missing
Financial strength, FY 2023 · tick: 2022
Weak
Solvency
0=
equity -76.9% of total assets
Liquidity
50=
short-term debt 4.1% · cash 0.2%
Profitability
14+14
return on assets -3.5%
Bankruptcy probability within 12 months
7.4%
Elevated
0%0.5%1.5%4%10%≥ 25%
About 7 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 1.0%
01-2025: 1.0%● unchanged vs 12-2024
02-2025: 1.0%● unchanged vs 01-2025
03-2025: 0.9%▼ -0.1 percentage points vs 02-2025
04-2025: 0.9%● unchanged vs 03-2025lowest value
05-2025: 0.9%● unchanged vs 04-2025
06-2025: 0.9%● unchanged vs 05-2025
07-2025: 1.0%▲ +0.1 percentage points vs 06-2025
08-2025: 2.2%▲ +1.2 percentage points vs 07-2025
09-2025: 2.6%▲ +0.4 percentage points vs 08-2025
10-2025: 3.5%▲ +0.9 percentage points vs 09-2025
11-2025: 3.8%▲ +0.3 percentage points vs 10-2025
12-2025: 4.4%▲ +0.6 percentage points vs 11-2025
01-2026: 5.5%▲ +1.1 percentage points vs 12-2025
02-2026: 5.5%● unchanged vs 01-2026
03-2026: 5.5%● unchanged vs 02-2026
04-2026: 5.0%▼ -0.5 percentage points vs 03-2026
05-2026: 5.0%● unchanged vs 04-2026
06-2026: 5.0%● unchanged vs 05-2026
07-2026: 5.1%▲ +0.1 percentage points vs 06-2026
08-2026: 6.7%▲ +1.6 percentage points vs 07-2026
09-2026: 6.7%● unchanged vs 08-2026
10-2026: 7.4%▲ +0.7 percentage points vs 09-2026highest value
11-2026: 7.4%● unchanged vs 10-2026highest value
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
raises risk · Two or more financial years not filed
Since the financial year that closed on 31-12-2024, 2 financial years are missing at the National Bank. A company this far behind goes bankrupt within the year nineteen times as often as a punctual filer.
NBB · 10 filingsPosition against the passed deadline
31-12-2024 year end31-07-2025 deadline02-11-2026 today
raises risk · 2023 accounts filed 29 days late
The financial year that closed on 31-12-2023 was due by 31-07-2024 and was filed on 29-08-2024, 29 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
not filed
2024
not filed
2023
29 days late
2022
31 days late
2021
on the day
2020
166 days late
2019
92 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 64 days after the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (1)
Key points
- Risk: Negative equitydebts exceed assets in financial year 2023 -€999,054 View
- Risk: 6 loss-making years in a rowloss in financial year 2023 -€44,940 View
- Caution: Less equity than 95% of companies in research and developmentsector median €142,252 · 593 companies -€999,054 View
- Positive: Result rose in 2023different schema filed ▲ 81.6% View
Recent changes
- · Gazette deed Registered office moved from Diegem to AsseResignations: HERBOTS Carine (director and chair of the board) and CABRI Jan (director)
- · Gazette deed Appointment: Anna CLOOF (director)
- · Gazette deed Appointment: HERBOTS Carine (director)Reappointments: DECONINCK Frank, ROELANT Chris and CABRI Jan · Resignation: ROELANT Chris (director)
Companies linked to PROTEA BIOPHARMA NV
Comparable companies
These companies have the same main activity as PROTEA BIOPHARMA NV: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €394,000 and €2.1m, founded between 2004 and 2017.
| Company | Total assets | Gross margin |
|---|---|---|
| PROTEA BIOPHARMA NV Asse | €1.3m | -€0.04m |
| STRATELYON BELGIUM Jette | €1.3m | €0.003m |
| ChemoSensoryX Biosciences SA Ottignies-Louvain-la-Neuve | €1.5m | -€0.6m |
| ORINEO Kortenberg | €0.4m | -€0.03m |
| ReWind Therapeutics Leuven | €2.1m | -€0.5m |
| 3.life Elsene | €0.8m | -€0.07m |
| IFAST Roeselare | €0.4m | -€0.05m |
Key facts about PROTEA BIOPHARMA NV
- What is the company number of PROTEA BIOPHARMA NV?
- The company number of PROTEA BIOPHARMA NV is 0820.421.545. The VAT number is the same number with BE in front: BE 0820.421.545.
- Where is PROTEA BIOPHARMA NV based?
- The registered office is at Huinegem 42, 1730 Asse.Company details
- What does PROTEA BIOPHARMA NV do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of PROTEA BIOPHARMA NV?
- The legal form of PROTEA BIOPHARMA NV is Public limited company (NV).
- When was PROTEA BIOPHARMA NV founded?
- PROTEA BIOPHARMA NV was founded on 10-11-2009.
- Is PROTEA BIOPHARMA NV still active?
- Yes, PROTEA BIOPHARMA NV is an active enterprise in the KBO register.
- How many employees does PROTEA BIOPHARMA NV have?
- PROTEA BIOPHARMA NV had an average of 0.4 full-time equivalents in financial year 2019, according to the filed annual accounts.Financials
- What is the turnover of PROTEA BIOPHARMA NV?
- The annual accounts for financial year 2023 state no turnover. The abbreviated or micro format does not require it.
- Is PROTEA BIOPHARMA NV profitable?
- In financial year 2023, PROTEA BIOPHARMA NV made a loss of €44,940.
- Where can I find the annual accounts of PROTEA BIOPHARMA NV?
- PROTEA BIOPHARMA NV filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2023.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.